HeartBeam has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its 12-lead electrocardiogram ...

SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ: BEAT), a $56.5 million market cap pioneer in medical technology currently trading at $2.12 per share, has announced the submission of a 510(k) ...

Electrocardiogram tests may someday be used with an artificial intelligence (AI) model to detect premature aging and cognitive decline, according to a preliminary study presented at the American ...

Advancements and Projections in the Global Cardiac Rhythm Management Devices Market: Insights, Trends, Opportunities, and ...

Electrocardiogram tests may someday be used with an artificial intelligence (AI) model to detect premature aging and cognitive decline, according to a preliminary study to be presented at the American ...

The FDA submission is backed by robust data from the VALID-ECG pivotal study, which enrolled 198 patients across five ...

HeartBeam (NASDAQ: BEAT) , a medical technology company advancing cardiac care, has submitted a 510 (k) application to the U.S. Food and Drug Administration (“FDA”) for its 12-lead electrocardiogram ( ...

Currently, Garmin’s ECG functionality only extends to on-the-spot readings and works to distinguish between normal sinus rhythms and signs of atrial fibrillation (AFib).